^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NKG2D CAR-NK cell therapy
i
Other names: NKG2D CAR-NK cell therapy, NKG2DL-specific CAR-NK cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hangzhou Cheetah Cell Therap
Drug class:
NK cell stimulant, NKG2DL-targeted CAR-T immunotherapy
Related drugs:
1year
NKG2D CAR-NK & r/rAML (clinicaltrials.gov)
P=N/A, N=9, Recruiting, Zhejiang University
New trial
|
NKG2D (killer cell lectin like receptor K1)
|
NKG2D CAR-NK cell therapy
over1year
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P=N/A, N=9, Terminated, Hangzhou Cheetah Cell Therapeutics Co., Ltd | Phase classification: P1 --> P=N/A | Recruiting --> Terminated; end
Phase classification • Trial termination
|
NKG2D (killer cell lectin like receptor K1)
|
NKG2D CAR-NK cell therapy
2years
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=9, Recruiting, Hangzhou Cheetah Cell Therapeutics Co., Ltd
New P1 trial
|
NKG2D (killer cell lectin like receptor K1)
|
NKG2D CAR-NK cell therapy
Share via
